Details for Patent: 8,273,779
✉ Email this page to a colleague
Which drugs does patent 8,273,779 protect, and when does it expire?
Patent 8,273,779 protects PONVORY and is included in one NDA.
This patent has thirty-four patent family members in twenty-five countries.
Summary for Patent: 8,273,779
Title: | Thiazolidin 4-one derivatives |
Abstract: | The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents. |
Inventor(s): | Binkert; Christoph (Basel, CH), Bolli; Martin (Allschwil, CH), Mathys; Boris (Egerkingen, CH), Mueller; Claus (Weil am Rhein, DE), Scherz; Michael (Ettingen, CH), Nayler; Oliver (Arlesheim, CH) |
Assignee: | Actelion Pharmaceuticals Ltd. (Allschwil, CH) |
Application Number: | 12/496,945 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,273,779
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-001 | Mar 18, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-002 | Mar 18, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-003 | Mar 18, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-004 | Mar 18, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-005 | Mar 18, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-006 | Mar 18, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,273,779
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
PCT/EP03/13072 | Nov 21, 2003 |
International Family Members for US Patent 8,273,779
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 047128 | ⤷ Try a Trial | |||
Austria | 483698 | ⤷ Try a Trial | |||
Australia | 2004295047 | ⤷ Try a Trial | |||
Brazil | PI0416752 | ⤷ Try a Trial | |||
Canada | 2545582 | ⤷ Try a Trial | |||
China | 100567275 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |